Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected

Executive Summary

Sanofi is putting more pressure on Medivation to accept its $9.3bn acquisition offer by proposing to replace the biotechnology company's and Xtandi developer's entire board of directors.

Advertisement

Related Content

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Medivation Gets Hostile After Sanofi's "Misleading" Maneuvers
Sanofi's New Diabetes & CV Head Guenter Has Difficult Job Ahead
Brandicourt Not Ready To Raise Medivation Bid Just Yet
Sanofi Earnings Emphasize Need For Medivation Buy
Sanofi Goes Public With Hostile Medivation Bid
Lantus Loss Drags Down Sanofi's Diabetes Franchise

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel